Previous 10 | Next 10 |
The European Commission (EC) granted orphan drug designation to Zynerba Pharmaceuticals' ( NASDAQ: ZYNE ) cannabidiol, the active ingredient in the company's transdermal gel Zygel, to treat 22q11.2 deletion syndrome (22q). The 22q11.2 deletion syndrome is a disord...
DEVON, Pa., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the European Commission (EC) has granted orphan d...
Zynerba Pharmaceuticals press release ( NASDAQ: ZYNE ): Q3 GAAP EPS of -$0.20 beats by $0.03 . As of September 30, 2022, cash and cash equivalents were $55.9 million, compared to $67.8 million as of December 31, 2021. Management believes that the Company’s c...
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with Fragile X syndrome (FXS); topline results expected second-half 2023 $55.9 million in cash and cash equivalents at September 30, 2022; Cash runway into first quarter 2024 ...
Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) said the U.S. Patent and Trademark Office issued a patent for its transdermal cannabidiol product candidate Zygel to treat 22q11.2 Deletion Syndrome. The patent No. 11,458,109 titled 'Treatment of 22q11.2 Deletion Syndrome ...
DEVON, Pa., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued P...
DEVON, Pa., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, presented a poster at the 2022 National Organization for Rare Disorder...
DEVON, Pa., Oct. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced the presentation of a poster at the 2022 National Orga...
Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has issued Patent No. 11,458,110, titled “Tre...
Zynerba Pharmaceuticals ( NASDAQ: ZYNE ) said the U.S. Patent and Trademark Office issued a patent covering methods of treating Fragile X syndrome (FXS) with cannabidiol. The patent no. 11,458,110, titled 'Treatment of Fragile X Syndrome With Cannabidiol' will expire i...
News, Short Squeeze, Breakout and More Instantly...
Zynerba Pharmaceuticals Inc. Company Name:
ZYNE Stock Symbol:
NASDAQ Market:
Zynerba Pharmaceuticals Inc. Website:
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE PR Newswire New product in development diversifies portfolio to drive long-term growth Innovative potential new therapeutic option for rare/orphan neuropsychiatric disorders w...
DEVON, Pa., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today reminds all stockholders, including individual stockholders, to prompt...
DEVON, Pa., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for orphan neuropsychiatric disorders, today released the following letter to stockholders concerning the pending ...